1. Search Result
Search Result
Results for "

β-catenin,structure-activity relationship

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

7

Screening Libraries

1

Biochemical Assay Reagents

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D1398

    nAChR Neurological Disease
    LtIA-F, a novel fluorescent analogue of LtIA, provides a wealth of pharmacological tools to explore the structure–function relationship, distribution, and ligand binding domain of the α3β2 nAChR subtype.
    LtIA-F
  • HY-N3919

    Others Cardiovascular Disease
    γ-Methoxyisoeugenol (Compound 5) is an anticoagulant agent that remarkably prolongs the thrombin time with a good dose-effect relationship at concentrations from 6.25 to 100 mM, but shows no significant differences in prothrombin time .
    γ-Methoxyisoeugenol
  • HY-123637

    Phosphodiesterase (PDE) Inflammation/Immunology
    Autotaxin-IN-1 is a potent autotaxin inhibitor, which has favorable potency (IC50=2.2 nM), PK properties, and a robust PK/PD relationship. Autotaxin-IN-1 is used in treatment of osteoarthritis pain .
    Autotaxin-IN-1
  • HY-101327

    Corwin; ICI 118587

    Adrenergic Receptor Cardiovascular Disease
    Xamoterol is a selective and potent agonist of beta1-adrenergic receptor. Xamoterol has the potential for the research of arrhythmogenesis. Xamoterol has the potential for the investigating the relationship between β1-adrenergic stimulation and IKr .
    Xamoterol
  • HY-120864

    Wnt Cancer
    SEN461 is a potent and orally active Wnt pathway inhibitor. SEN461 shows effective anti-tumor activity and can be used for GBM research .
    SEN461
  • HY-101327A

    Corwin hemifumarate; ICI 118587 hemifumarate

    Adrenergic Receptor Cardiovascular Disease
    Xamoterol hemifumarate is a selective and potent agonist of beta1-adrenergic receptor. Xamoterol hemifumarate has the potential for the research of arrhythmogenesis. Xamoterol hemifumarate has the potential for the investigating the relationship between β1-adrenergic stimulation and IKr .
    Xamoterol hemifumarate
  • HY-146260

    PI3K Cancer
    NVP-CLR457 (compound 40) is an orally active, potent and balanced pan-class I PI3K inhibitor. NVP-CLR457 shows a clear dose-dependent PK/PD/efficacy relationship. NVP-CLR457 has antitumor activity .
    NVP-CLR457
  • HY-155316

    Others Others
    5-HT6R antagonist 2 (compound 29) is a 5-HT6 receptor antagonist .
    5-HT6R antagonist 2
  • HY-106577

    Cifenline; Ro 22-7796

    Potassium Channel Cardiovascular Disease
    Cibenzoline is a potent inhibitor of KATP channel with directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline is a class Ia antiarrhythmic agent. Cibenzoline has little anticholinergic activity. Cibenzoline markedly attenuate LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for the research of hypertrophic obstructive cardiomyopathy .
    Cibenzoline
  • HY-155836

    Others Metabolic Disease
    hPL-IN-1 (compound 2t) is a reversible inhibitor of pancreatic lipase (PL) (IC50=1.86 μM) for anti-obesity research .
    hPL-IN-1
  • HY-155837

    Others Metabolic Disease
    hPL-IN-2 (compound 2u) is a potent, reversible, and non-competitive inhibitor of pancreatic lipase (IC50: 1.63 μM) and can be used in anti-obesity research .
    hPL-IN-2
  • HY-14178A

    ERK Others
    (R)-VX-11e (Compound 1) is an ERK2 inhibitor .
    (R)-VX-11e
  • HY-118851

    Others Others
    NSC-77053 is a potent BoNT/E inhibitor with an IC50 and a Ki of 2.4 μM and 1.29 μM, respectively .
    NSC-77053
  • HY-75680

    Factor Xa Cardiovascular Disease
    FaX-IN-1 (compound 11A) is an intermediate in the preparation of FaX inhibitors and was used to study the inhibitory activity against venous thrombosis in rats .
    FaX-IN-1
  • HY-124424

    Potassium Channel Others Neurological Disease
    VU0071063 is a potent and specific Kir6.2/SUR1 opener (EC50=7.44 μM) and can be used for investigating Kir6.2/SUR1 expressed in the pancreas and brain. VU0071063 inhibits insulin secretion by inducing hyperpolarization of β-cell membrane potential. VU0071063 chemotype has a very steep structure-activity relationships .
    VU0071063
  • HY-157928

    Keap1-Nrf2 Inflammation/Immunology
    Keap1-Nrf2-IN-18 (Compound 22) is an orally active Keap1-Nrf2 protein-protein interaction (PPI) inhibitor with good pharmacokinetics (PK) profiles and more potent in vivo activities in rats. Keap1-Nrf2-IN-18 has the strongest inhibitory activity in structureactivity relationship (SAR) study (KD = 0.0029 μM) .
    Keap1-Nrf2-IN-18
  • HY-106577R

    Potassium Channel Cardiovascular Disease
    Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a potent inhibitor of KATP channel with directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline is a class Ia antiarrhythmic agent. Cibenzoline has little anticholinergic activity. Cibenzoline markedly attenuate LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for the research of hypertrophic obstructive cardiomyopathy .
    Cibenzoline (Standard)
  • HY-155138

    Glutaminase Metabolic Disease Cancer
    GLS1 Inhibitor-7 (compound 4d) is a GLS1 inhibitor (IC50=46.7 μM), with potential anti-cancer, anti-aging and anti-obesity properties .
    GLS1 Inhibitor-7
  • HY-149524

    Sirtuin Cancer
    SIRT5 inhibitor 8 (compound 10) is a competitive inhibitor (IC50: 5.38 μM) of sirtuin SIRT5 with anticancer potential .
    SIRT5 inhibitor 8
  • HY-149525

    Sirtuin Cancer
    SIRT5 inhibitor 9 (compound 14) is a competitive inhibitor (IC50: 4.07 μM) of sirtuin SIRT5 with anticancer potential .
    SIRT5 inhibitor 9
  • HY-156094

    HDAC Histone Demethylase Apoptosis Cancer
    JMJD3/HDAC-IN-1 (compound A5b) is a dual inhibitor targeting Jumonji domain-containing protein demethylase 3 (JMJD3) and histone deacetylase (HADC1, IC50=16 nM). JMJD3/HDAC-IN-1 promotes hypermethylation of histone H3K27 and hyperacetylation of H3K9, and also cleaves caspase-7 and PARP to induce apoptosis. JMJD3/HDAC-IN-1 effectively inhibits cancer cell cloning, migration, and invasion .
    JMJD3/HDAC-IN-1
  • HY-145860

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PHGDH-IN-2 is a potent and NAD + competitive PHGDH inhibitor with an IC50 of 5.2 µM. PHGDH-IN-2 inhibits the serine synthetic pathway in MDA-MB-468 cells. PHGDH-IN-2 inhibits the growth of PHGDH-dependent cancer cells .
    PHGDH-IN-2
  • HY-120371

    Others Inflammation/Immunology
    CPUY192018 is a potent Keap1-Nrf2-ARE inhibitor with an IC50 of 0.63 µM. CPUY192018 exhibits induction of Nrf2-dependent gene NQO1 at 100 µM .
    CPUY192018
  • HY-158028

    Influenza Virus Infection
    PAN endonuclease-IN-2 (compound T-31) is a PAN endonuclease inhibitor (IC50: 0.15 μM) and antiviral agent with broad-spectrum anti- Influenza activity. PAN is the N-terminal PA subunit of the polymerase-RNA complex and the dependent endonuclease (CEN) active site. PAN initiates RNA replication by promoting cleavage of the RNA strand and allowing the polymerase to begin synthesizing new RNA molecules. PAN endonuclease-IN-2 targets both the influenza HA and RdRp complexes, thereby interfering with viral entry into host cells and viral replication .
    PAN endonuclease-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: